Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : analysts and calls -- Morgan Stanley -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (12)	10/16/2002 1:14:30 PM
From: scaram(o)uche	Respond to of 31

11/03/00...... hairlosssucks.com The robust spending mixed with discoveries based on the human genome project and a better understanding of the immune system enhances the fundamentals of the sector. "We are seeing a ton of good news and lots of products moving through the pipeline right now, so I think fundamentals are moving the sector," said Robertson Stephens analyst Steve Harr. Analysts said more North American biotech companies have drugs in late stages of clinical trials than ever before. 8/5/01....... smarts.com.au "The overall biotech market has been relatively soft over the last several weeks," said Steve Harr, a research analyst with Robertson Stephens. But Harr said the company's stock also dropped in mid-July on news of a delay in FDA approval for Chiron's nucleic acid testing product (NAT), which screens blood for HIV and hepatitis. The company's stock was downgraded last month by Robertson Stephens to "market under-perform" from "market perform." Harr said he looks for insider trading by executives before major events, such as FDA action. He said Chiron has a diverse portfolio of products, but he remained cautious. "We are not the most bullish group on the Street about this stock," he said. "Our impression is they are entering a period of relatively slow earnings growth." Chiron has shown relative strength since then, and is barely down. The market and cancer vaccine calls in November 2000 don't look particularly insightful, IMO. First blush, Harr looks like a contrary indicator.